A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (NCT07141706)
A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Who can join: Review the eligibility criteria below.
Location: USA04-0 — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- USA04-0 — Los Angeles, California
- USA05-0 — Ann Arbor, Michigan
- Site USA06-0 — Pittsburgh, Pennsylvania
- USA02-0 — Houston, Texas
- USA03-0 — San Antonio, Texas
- USA01-0 — Fairfax, Virginia
- AUS03-0 — Liverpool, New South Wales
- AUS01-0 — Randwick, New South Wales
- AUS04-0 — Westmead, New South Wales
- AUS02-0 — Nedlands, Western Australia
- Chn01-1/Chn01-2 — Guangzhou, Guangdong
- CHN05-0 — Harbin, Heilongjiang
- CHN03-0 — Zhengzhou, Henan
- CHN04-0 — Jinan, Shandong
📞 Contact the Study Coordinator
Phone: 01067228087
Email: junhua.gao@dualitybiologics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced/Metastatic Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — Duarte, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — La Jolla, California
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — Scottsdale, Arizona
Explore by condition: All Advanced/Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.